Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373

Boosters of adjuvanted NVX-CoV2373 protein vaccine led to increasing neutralizing titers of antibody specific for the ancestral strain and omicron variants. Whether the elicited antibodies protect against infection is unclear.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 388; no. 9; pp. 857 - 859
Main Authors Alves, Katia, Plested, Joyce S., Galbiati, Shirley, Chau, Gordon, Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Smith, Kathy, Marcheschi, Alex, Pfeiffer, Susan, McFall, Heather, Smith, Gale, Glenn, Gregory M., Dubovsky, Filip, Mallory, Raburn M.
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 02.03.2023
Subjects
Cartography
Coronavirus
Coronaviruses
Correspondence
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - immunology
Disease transmission
Humans
Immunogenicity
Immunogenicity, Vaccine - immunology
Infectious Disease
Proteins
Severe acute respiratory syndrome coronavirus 2
Software
Vaccines
Viral Infections
Online AccessGet full text

Cover

More Information
Summary:Boosters of adjuvanted NVX-CoV2373 protein vaccine led to increasing neutralizing titers of antibody specific for the ancestral strain and omicron variants. Whether the elicited antibodies protect against infection is unclear.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2215509